Equities Research Analysts’ updated eps estimates for Thursday, November 14th:
Acrivon Therapeutics (NASDAQ:ACRV) had its buy rating reissued by analysts at HC Wainwright. The firm currently has a $22.00 target price on the stock.
Acurx Pharmaceuticals (NASDAQ:ACXP) had its buy rating reiterated by analysts at HC Wainwright. They currently have a $12.00 target price on the stock.
Alumis (NASDAQ:ALMS) had its overweight rating reissued by analysts at Cantor Fitzgerald.
Altimmune (NASDAQ:ALT) had its buy rating reissued by analysts at HC Wainwright. The firm currently has a $12.00 price target on the stock.
Ardent Health Partners (NYSE:ARDT) had its outperform rating reissued by analysts at Royal Bank of Canada. They currently have a $23.00 target price on the stock.
Avino Silver & Gold Mines (NYSE:ASM) had its buy rating reaffirmed by analysts at Roth Mkm. Roth Mkm currently has a $1.80 target price on the stock, down from their previous target price of $1.90.
Avino Silver & Gold Mines (NYSE:ASM) had its buy rating reissued by analysts at Roth Mkm. Roth Mkm currently has a $1.80 price target on the stock, down from their previous price target of $1.90.
Aura Biosciences (NASDAQ:AURA) had its buy rating reiterated by analysts at HC Wainwright. They currently have a $22.00 price target on the stock.
Biohaven (NYSE:BHVN) had its buy rating reaffirmed by analysts at HC Wainwright. The firm currently has a $59.00 price target on the stock.
Bitfarms (NASDAQ:BITF) had its buy rating reissued by analysts at HC Wainwright. HC Wainwright currently has a $4.00 price target on the stock.
BioNTech (NASDAQ:BNTX) had its buy rating reissued by analysts at Canaccord Genuity Group Inc.. The firm currently has a $171.00 price target on the stock.
Beachbody (NYSE:BODI) had its buy rating reiterated by analysts at Roth Mkm. The firm currently has a $12.00 price target on the stock.
Boxlight (NASDAQ:BOXL) had its buy rating reiterated by analysts at HC Wainwright. They currently have a $1.00 price target on the stock.
CalciMedica (NASDAQ:CALC) had its buy rating reissued by analysts at HC Wainwright. The firm currently has a $16.00 price target on the stock.
Clene (NASDAQ:CLNN) had its buy rating reaffirmed by analysts at HC Wainwright. HC Wainwright currently has a $31.00 target price on the stock.
Clearside Biomedical (NASDAQ:CLSD) had its buy rating reaffirmed by analysts at HC Wainwright. The firm currently has a $6.00 target price on the stock.
Complete Solaria (NASDAQ:CSLR) had its overweight rating reissued by analysts at Cantor Fitzgerald. Cantor Fitzgerald currently has a $6.00 target price on the stock.
CyberArk Software (NASDAQ:CYBR) had its buy rating reiterated by analysts at Truist Financial Co.. They currently have a $350.00 target price on the stock, up from their previous target price of $300.00.
CyberArk Software (NASDAQ:CYBR) had its overweight rating reiterated by analysts at Cantor Fitzgerald. Cantor Fitzgerald currently has a $335.00 target price on the stock.
Digi International (NASDAQ:DGII) had its hold rating reiterated by analysts at Craig Hallum. They currently have a $32.00 target price on the stock, up from their previous target price of $28.00.
DURECT (NASDAQ:DRRX) had its neutral rating reiterated by analysts at HC Wainwright.
Dyadic International (NASDAQ:DYAI) had its buy rating reiterated by analysts at HC Wainwright. They currently have a $6.00 price target on the stock.
Forian (NASDAQ:FORA) had its buy rating reissued by analysts at Roth Mkm. Roth Mkm currently has a $5.00 target price on the stock.
Fulcrum Therapeutics (NASDAQ:FULC) had its sector perform rating reaffirmed by analysts at Royal Bank of Canada. The firm currently has a $4.00 target price on the stock.
Fulcrum Therapeutics (NASDAQ:FULC) had its neutral rating reaffirmed by analysts at HC Wainwright. HC Wainwright currently has a $4.00 price target on the stock.
Formula One Group (NASDAQ:FWONA) had its buy rating reissued by analysts at Benchmark Co.. Benchmark Co. currently has a $81.00 target price on the stock.
ESS Tech (NYSE:GWH) had its hold rating reissued by analysts at Canaccord Genuity Group Inc.. Canaccord Genuity Group Inc. currently has a $8.00 price target on the stock.
Integral Ad Science (NASDAQ:IAS) had its hold rating reiterated by analysts at Benchmark Co..
Intellicheck (NYSE:IDN) had its buy rating reissued by analysts at HC Wainwright. The firm currently has a $4.00 price target on the stock.
Immuneering (NASDAQ:IMRX) had its buy rating reaffirmed by analysts at Needham & Company LLC. They currently have a $15.00 price target on the stock.
Loar (NYSE:LOAR) had its outperform rating reaffirmed by analysts at Royal Bank of Canada. They currently have a $100.00 target price on the stock.
Liquidia (NASDAQ:LQDA) had its buy rating reissued by analysts at Needham & Company LLC. The firm currently has a $19.00 price target on the stock.
Lucid Diagnostics (NASDAQ:LUCD) had its buy rating reiterated by analysts at Needham & Company LLC. They currently have a $2.50 price target on the stock.
Lucid Diagnostics (NASDAQ:LUCD) had its buy rating reiterated by analysts at Canaccord Genuity Group Inc.. Canaccord Genuity Group Inc. currently has a $3.00 price target on the stock.
Mastercard (NYSE:MA) had its outperform rating reiterated by analysts at Royal Bank of Canada. They currently have a $572.00 price target on the stock.
Seres Therapeutics (NASDAQ:MCRB) had its buy rating reiterated by analysts at Canaccord Genuity Group Inc.. They currently have a $10.00 price target on the stock.
MoonLake Immunotherapeutics (NASDAQ:MLTX) had its buy rating reiterated by analysts at HC Wainwright. They currently have a $100.00 price target on the stock.
Topgolf Callaway Brands (NYSE:MODG) had its buy rating reissued by analysts at Roth Mkm. Roth Mkm currently has a $16.00 price target on the stock, down from their previous price target of $17.00.
Mosaic (NYSE:MOS) had its sector perform rating reaffirmed by analysts at Royal Bank of Canada. They currently have a $30.00 price target on the stock.
Marinus Pharmaceuticals (NASDAQ:MRNS) had its neutral rating reaffirmed by analysts at HC Wainwright. HC Wainwright currently has a $2.00 price target on the stock.
Marinus Pharmaceuticals (NASDAQ:MRNS) had its overweight rating reiterated by analysts at Cantor Fitzgerald. Cantor Fitzgerald currently has a $4.00 price target on the stock.
NICE (NASDAQ:NICE) had its neutral rating reiterated by analysts at Piper Sandler.
NVIDIA (NASDAQ:NVDA) had its outperform rating reissued by analysts at Wedbush. Wedbush currently has a $160.00 price target on the stock, up from their previous price target of $138.00.
OmniAb (NASDAQ:OABI) had its buy rating reaffirmed by analysts at HC Wainwright. They currently have a $11.00 target price on the stock.
OmniAb (NASDAQ:OABI) had its buy rating reiterated by analysts at Benchmark Co.. The firm currently has a $8.00 price target on the stock.
Omeros (NASDAQ:OMER) had its hold rating reaffirmed by analysts at Needham & Company LLC.
Omeros (NASDAQ:OMER) had its neutral rating reiterated by analysts at Cantor Fitzgerald.
Oncolytics Biotech (NASDAQ:ONCY) had its buy rating reissued by analysts at HC Wainwright. They currently have a $5.00 price target on the stock.
OptimizeRx (NASDAQ:OPRX) had its buy rating reaffirmed by analysts at Roth Mkm. The firm currently has a $16.00 target price on the stock, down from their previous target price of $20.00.
Passage Bio (NASDAQ:PASG) had its buy rating reissued by analysts at Canaccord Genuity Group Inc.. Canaccord Genuity Group Inc. currently has a $13.00 target price on the stock.
Rigetti Computing (NASDAQ:RGTI) had its buy rating reissued by analysts at Benchmark Co.. Benchmark Co. currently has a $2.50 target price on the stock.
Riskified (NYSE:RSKD) had its overweight rating reaffirmed by analysts at Piper Sandler. Piper Sandler currently has a $7.00 price target on the stock.
Smith Micro Software (NASDAQ:SMSI) had its buy rating reaffirmed by analysts at Benchmark Co.. They currently have a $5.00 target price on the stock.
Protara Therapeutics (NASDAQ:TARA) had its buy rating reaffirmed by analysts at HC Wainwright. They currently have a $23.00 target price on the stock.
Target Hospitality (NASDAQ:TH) had its market perform rating reaffirmed by analysts at Oppenheimer Holdings Inc..
Tower Semiconductor (NASDAQ:TSEM) had its buy rating reaffirmed by analysts at Benchmark Co.. The firm currently has a $55.00 price target on the stock.
Voyager Therapeutics (NASDAQ:VYGR) had its buy rating reaffirmed by analysts at Canaccord Genuity Group Inc.. Canaccord Genuity Group Inc. currently has a $14.00 target price on the stock.
Voyager Therapeutics (NASDAQ:VYGR) had its buy rating reiterated by analysts at HC Wainwright. HC Wainwright currently has a $30.00 price target on the stock.
Westport Fuel Systems (NASDAQ:WPRT) (TSE:WPRT) had its sector perform rating reissued by analysts at Royal Bank of Canada. Royal Bank of Canada currently has a $8.00 target price on the stock.
WidePoint (NYSEAMERICAN:WYY) had its buy rating reaffirmed by analysts at HC Wainwright. They currently have a $7.00 price target on the stock.
YETI (NYSE:YETI) had its hold rating reaffirmed by analysts at Canaccord Genuity Group Inc.. They currently have a $44.00 target price on the stock.
Yatra Online (NASDAQ:YTRA) had its buy rating reiterated by analysts at HC Wainwright. They currently have a $4.00 price target on the stock.
Receive News & Ratings for Acrivon Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acrivon Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.